多聚免疫球蛋白受体（pIgR）在粘膜免疫中的重要功能

多聚免疫球蛋白受体（pIgR）属于Ⅰ型跨膜糖蛋白,可与多聚免疫球蛋白A和多聚免疫球蛋白M特异性结合,通过穿胞转运,将它们从上皮细胞基底侧膜转运到顶膜,并最终分泌到外分泌液中去. 在此过程中,多聚免疫球蛋白受体的细胞外段被水解,释放出与多聚免疫球蛋白A或多聚免疫球蛋白M相结合的细胞外段（又称为分泌成分）. 分泌成分是sIgA分子的重要组成部分,直接参与sIgA的粘膜防御功能,而且在被动粘膜免疫中也有重要作用. 多聚免疫球蛋白受体通过介导细胞内多聚免疫球蛋白的转运,可以在粘膜的腔面阻止病原体粘附,在上皮细胞内中和病毒,也可以将固有层内的抗原分泌出去. 因此,多聚免疫球蛋白受体的有效分泌是多聚免疫球蛋白发挥粘膜防御功能的必要条件. 但在某些情况下,该受体也可以介导微生物对上皮屏障的入侵. 多聚免疫球蛋白受体是高度 N -糖基化的,其分子中独特的糖链结构,可能与受体的穿胞转运、sIgA在粘膜的正确定位,以及抗原对上皮细胞的粘附有关. 多聚免疫球蛋白受体和分泌成分参与的多重分子机制,使它们在粘膜免疫中起着举足轻重的作用.     

膜铁转运蛋白Ferroportin 1的研究进展

膜铁转运蛋白Ferroportin 1(2000年发现)在细胞铁的输出中起重要作用。它在成熟的十二指肠绒毛上皮细胞基底面、脾和肝的巨噬细胞、胎盘的合体滋养层细胞等都有表达。经序列分析显示Ferroportin 1具有十个跨膜结构域、一个还原酶位点和一个基底定位信号位点。此外,Ferroportin 1 mRNA转录在5’非翻译区包含一个铁反应元件。本文对Ferroportin 1的目前研究进行了综述,并阐述了其医学应用前景。     

人慢性胃炎粘膜内CD3+细胞,S-100+树突状细胞和nNOS表达的意义

采用免疫细胞化学方法探讨胃粘膜内CD3+细胞,S-100+树突状细胞和nNOS的表达与慢性胃炎的关系及意义.检测标本均取自胃窦部活检的胃粘膜组织.结果显示CD3+细胞主要分布于粘膜上皮、腺上皮和固有膜内,而S-100+树突状细胞则主要位于固有膜内,正常组与浅表性胃炎组和萎缩性胃炎组,浅表性胃炎组与萎缩性胃炎组细胞数量有显著性差异( P<0.01),nNOS阳性反应主要位于粘膜上皮和腺上皮的基底部,但各组之间nNOS的表达程度不同,特别是萎缩性胃炎与浅表性胃炎有显著性差异(P<0.01),我们认为,对CD3+ 细胞,S-100 +树突状细胞和nNOS的检测,不仅有助于判断胃炎的病变程度和临床疗效,而且也为胃炎的治疗提供新的启示.     

人慢性胃炎粘膜内CD3+细胞,S-100+树突状细胞和nNOS表达的意义

采用免疫细胞化学方法探讨胃粘膜内 CD3+细胞 ,S- 10 0 +树突状细胞和 n NOS的表达与慢性胃炎的关系及意义。检测标本均取自胃窦部活检的胃粘膜组织。结果显示 CD3+细胞主要分布于粘膜上皮、腺上皮和固有膜内 ,而 S- 10 0 +树突状细胞则主要位于固有膜内 ,正常组与浅表性胃炎组和萎缩性胃炎组 ,浅表性胃炎组与萎缩性胃炎组细胞数量有显著性差异(P<0 .0 1) ,n NOS阳性反应主要位于粘膜上皮和腺上皮的基底部 ,但各组之间 n NOS的表达程度不同 ,特别是萎缩性胃炎与浅表性胃炎有显著性差异 (P<0 .0 1) ,我们认为 ,对 CD3+细胞 ,S- 10 0 +树突状细胞和 n NOS的检测 ,不仅有助于判断胃炎的病变程度和临床疗效 ,而且也为胃炎的治疗提供新的启示     

鼠伤寒沙门菌感染巨噬细胞铁稳态相关基因mRNA表达谱

用荧光定量PCR法检测鼠RAW264.7巨噬细胞感染与未感染鼠伤寒沙门菌后18种铁穗态相关基因的表达,评估宿主与病原体相互作用中铁稳态效应。研究显示,活的鼠伤寒沙门菌感染巨噬细胞1 h后可以诱导转铁蛋白受体表达,引起细胞内动态铁池相关基因的mRNA水平上长。基因表达分析显示,沙门菌通过诱导铁氧还原酶(Steap3)、铁膜转运蛋白(Dmt1)、铁调节因子Tfr2/Hfe以及铁调节蛋白(Irp1和Irp2)的表达主动吸收铁,而经铁转运蛋白(Fpn1)的铁外流并无明显改变。沙门菌在感染后1h积极地驱动了转铁蛋白介导的铁吸收程序。     

不同剂量右美托咪定对妇科腹腔镜手术患者应激反应、血流动力学和术后认知功能的影响

摘要 目的：探讨不同剂量右美托咪定对妇科腹腔镜手术患者血流动力学、术后认知功能以及应激反应的影响。方法：选取2016年3月～2018年5月在我院行妇科腹腔镜手术的150例患者,按照随机数字表法分为甲、乙、丙三组,各50例,甲组在麻醉诱导后以0.8 μg?kg-1?h-1的速率输注右美托咪定,乙组在麻醉诱导后以0.4 μg?kg^-1?h^-1的速率输注右美托咪定,丙组给予患者注射等量生理盐水,对比不同时间点三组患者血流动力学变化情况、应激指标、麻醉恢复时间、气腹时间、拔管时间、麻醉恢复室（PACU）停留时间、改良镇静-躁动评分(RASS)、不良反应发生率,统计患者术后认知功能障碍 (POCD)发生情况。结果：T0（麻醉诱导前10 min）时,三组HR、MAP对比差异无统计学意义（P＞0.05）;T1（气管插管后1 min）、T2（气腹后5 min）时,甲组、乙组HR、MAP均低于丙组,甲组HR、MAP低于乙组（P＜0.05）;T3（术毕）时,甲组、乙组HR均低于丙组（P＜0.05）,甲、乙、丙三组MAP对比,差异无统计学意义（P＞0.05）。甲、乙两组术后1 h、6 h、12 h时RASS评分均低于丙组（P＜0.05）,甲组术后1 h、6 h、12 h时RASS评分低于乙组（P＜0.05）;T1、T2、T3时,甲组、乙组去甲肾上腺素（NA）、促肾上腺皮质激素（ACTH）水平均低于丙组,甲组NA、ACTH水平均低于乙组（P＜0.05）。甲、乙组拔管时间、PACU停留时间均短于丙组,甲组短于乙组（P＜0.05）。甲组、乙组、丙组术后POCD发生率为2.00%（1/50）、10.00%（5/50）、24.00%（12/50）,甲组POCD发生率低于丙组（P＜0.05）。三组麻醉恢复时间、气腹时间、不良反应发生率相比较,差异无统计学意义（P＞0.05）。结论：妇科腹腔镜术患者围术期应用右美托咪定有利于维持血流动力学稳定,减轻应激反应,降低术后认知功能障碍发生率,其中0.8 μg?kg^-1?h^-1右美托咪定作用更明显。     

扬子鳄消化道嗜银细胞的分布及形态学观察

该文用龙桂开浸银法对扬子鳄消化道嗜银细胞的分布及形态进行了观察。结果表明：嗜银细胞分布于整个消化道中，从食道到直肠。其中，十二指肠和回、直肠交接处密度很高，胃体及直肠很低。嗜银细胞形态多样。食道嗜银细胞位于上皮基部和固有膜中，呈椭圆形或不规则形。胃嗜银细胞位于胃腺部，圆形或椭圆形，有的可见明显的胞突。肠嗜银细胞位于上皮细胞之间，呈长柱形、纺锤形、长颈瓶形或锤状。多数细胞两端有较长胞突，分别与固有膜     

24p3/NGAL介导的铁转运途径

生物体内存在另一转铁途径。脂笼蛋白(lipocalin)家族的成员24p3／NGAL介导铁向细胞内转运,并在具有酸性环境的核内体(endosome)中与铁解离,进而调节铁蛋白(ferritin,Fn)基因和转铁蛋白受体-1(transferrin receptor-1,TfR-1)基因的表达。24p3／NGA转铁途径在亚细胞水平上与转铁蛋白(tansferrin,Tf)类似但相互独立。在胚肾发育过程中,24p3／NGAL与Tf介导的铁转运途径为不同时期的原始肾上皮细胞生长与分化所必需。深入研究24p3／NGAL转铁途径的分子机制及与Tf的异同有十分重要的意义。     

香鱼消化道及肝脏的形态结构特征

采用解剖及石蜡切片显微技术观察了香鱼消化道及肝脏的组织学结构。香鱼消化道由口咽腔、食道、胃及肠构成。口咽腔大且狭长,其底壁前部有一对粘膜褶,两颌边缘着生宽扁梳状齿,腭骨及舌骨具齿,犁骨无齿;舌由基舌骨突出部分覆盖粘膜构成,舌粘膜上皮为复层扁平上皮,含有较多的杯状细胞和味蕾。食道、胃及肠均由粘膜层、粘膜下层、肌层及外膜构成。食道粘膜层上皮为复层扁平上皮,杯状细胞发达。胃呈V形,由贲门部、胃体部及幽门部组成,胃壁粘膜上皮为单层柱状上皮,贲门部与胃体部的固有层中有胃腺。肠较短,由前、中、后肠构成,肠壁粘膜上皮为单层柱状上皮,其游离面具微绒毛;上皮细胞间有杯状细胞。幽门盲囊有350～400条,其组织学结构与肠相同。肝脏单叶,外被浆膜;肝细胞形态不规则,肝小叶界限不明显。     

卵巢切除对大鼠子宫阴道雌激素受体亚型表达的影响

目的 通过观察雌激素受体亚型在去势大鼠子宫和阴道的表达, 研究卵巢切除对大鼠子宫、阴道的影响机制.方法 60只成年SD雌性大鼠随机分为正常组、假手术组、去势组,每组20只.8周后处死大鼠,分离摘取子宫、阴道,进行ERα、ERβ免疫组织化学染色和mRNA半定量RT-PCR检测.结果 ERα在各组子宫内膜上皮细胞、间质细胞及平滑肌细胞中均有表达,以内膜腔上皮和腺上皮细胞表达最强;ERα在各组阴道粘膜上皮细胞、间质细胞及平滑肌细胞中均有表达,以粘膜上皮细胞中表达最强.去势组子宫、阴道ERα表达水平较其它两组明显降低.ERβ主要在正常组和假手术组子宫内膜腔上皮细胞、腺上皮细胞和阴道粘膜上皮细胞中有表达,但较ERα表达弱.ERβ在去势大鼠子宫和阴道中未见明显表达.正常组和假手术组子宫、阴道雌激素受体亚型的表达强度和分布无明显差异.结论 卵巢切除后大鼠子宫、阴道ER亚型表达明显降低,尤其以ERβ表达下调明显.     

Gene expression of divalent metal transporter 1 and transferrin receptor in duodenum of Belgrade rats

Regulation of iron absorption is thought to be mediated by the amount of iron taken up by duodenal crypt cells via the transferrin receptor (TfR)-transferrin cycle and the activity of the divalent metal transporter (DMT1), although DMT1 cannot be detected morphologically in crypt cells. We investigated the uptake of transferrin-bound iron by duodenal enterocytes in Wistar rats fed different levels of iron and Belgrade (b/b) rats in which iron uptake by the transferrin cycle is defective because of a mutation in DMT1. We showed that DMT1 in our colony of b/b rats contains the G185R mutation, which in enterocytes results in reduced cellular iron content and increased DMT1 gene expression similar to levels in iron deficiency of normal rats. In all groups the uptake of transferrin-bound iron by crypt cells was directly proportional to plasma iron concentration, being highest in iron-loaded Wistar rats and b/b rats. We conclude that the uptake of transferrin-bound iron by developing enterocytes is largely independent of DMT1.     

Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3

Hereditary hemochromatosis type 3 is an iron (Fe)-overload disorder caused by mutations in transferrin receptor 2 (TfR2). TfR2 is expressed highly in the liver and regulates Fe metabolism. The aim of this study was to investigate duodenal Fe absorption and hepatic Fe uptake in a TfR2 (Y245X) mutant mouse model of hereditary hemochromatosis type 3. Duodenal Fe absorption and hepatic Fe uptake were measured in vivo by 59Fe-labeled ascorbate in TfR2 mutant mice, wild-type mice, and Fe-loaded wild-type mice (2% dietary carbonyl Fe). Gene expression was measured by real-time RT-PCR. Liver nonheme Fe concentration increased progressively with age in TfR2 mutant mice compared with wild-type mice. Fe absorption (both duodenal Fe uptake and transfer) was increased in TfR2 mutant mice compared with wild-type mice. Likewise, expression of genes participating in duodenal Fe uptake (Dcytb, DMT1) and transfer (ferroportin) were increased in TfR2 mutant mice. Nearly all of the absorbed Fe was taken up rapidly by the liver. Despite hepatic Fe loading, hepcidin expression was decreased in TfR2 mutant mice compared with wild-type mice. Even when compared with Fe-loaded wild-type mice, TfR2 mutant mice had increased Fe absorption, increased duodenal Fe transport gene expression, increased liver Fe uptake, and decreased liver hepcidin expression. In conclusion, despite systemic Fe loading, Fe absorption and liver Fe uptake were increased in TfR2 mutant mice in association with decreased expression of hepcidin. These findings support a model in which TfR2 is a sensor of Fe status and regulates duodenal Fe absorption and liver Fe uptake.     

Co-localization of the mammalian hemochromatosis gene product (HFE) and a newly identified transferrin receptor (TfR2) in intestinal tissue and cells.

Mutations in the HFE gene and a newly identified second transferrin receptor gene, TfR2, cause hemochromatosis. The cognate proteins, HFE and TfR2, are therefore of key importance in human iron homeostasis. HFE is expressed in small intestinal crypt cells where transferrin-iron entry may determine subsequent iron absorption by mature enterocytes, but the physiological function of TfR2 is unknown. Using specific peptide antisera, we examined the duodenal localization of HFE and TfR2 in humans and mice, with and without HFE deficiency, by confocal microscopy. We also investigated potential interactions of these proteins in human intestinal cells in situ. Duodenal expression of HFE and TfR2 (but not TfR1) in wild-type mice and humans was restricted to crypt cells, in which they co-localized. HFE deficiency disrupted this interaction, altering the cellular distribution of TfR2 in human crypts. In human Caco-2 cells, HFE and TfR2 co-localized to a distinct CD63-negative vesicular compartment showing marked signal enhancement on exposure to iron-saturated transferrin ligand, indicating that HFE preferentially interacts with TfR2 in a specialized early endosomal transport pathway for transferrin-iron. This interaction occurs specifically in small intestinal crypt cells that differentiate to become iron-absorbing enterocytes. Our immunohistochemical findings provide evidence for a novel mechanism for the regulation of iron balance in mammals.     

Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis

We investigated the effects of the iron chelator desferrioxamine on the expression of transferrin receptors (TfR) by CCRF-CEM human T-cell leukaemia and B16 mouse melanoma cells growing in tissue culture. Desferrioxamine (DFOA) enhanced TfR expression when added in the dose range of 10(-5)-10(-4) to CCRF-CEM cells, but was toxic to these cells, the lower concentrations producing a slowing of cell growth with a build up in S-phase, while higher concentrations caused cell death with a block at the G1/S-phase interface. These toxic effects are compatible with its previously reported inhibition of the non-haem iron containing (M2) subunit of ribonucleotide reductase. In marked contrast, DFOA caused the growth of B16 melanoma cells to arrest in G1, without loss of cloning efficiency, and resulted in a fall in TfR expression to approximately 50% of control values. These results suggested that the effects of DFOA on TfR expression were linked to DNA synthesis rather than to a more generalised inhibition of iron-dependent cellular processes. It was subsequently found that inhibition of the M2 subunit of ribonucleotide reductase in CCRF-CEM cells with 5 X 10(-5) M hydroxyurea, which is not an iron chelator, also enhanced TfR expression, as did thymidine and cytosine arabinoside, which have different enzyme targets. By measuring cellular DNA and RNA content simultaneously it was shown that all of these agents caused unbalanced growth, i.e., inhibited DNA synthesis more than RNA synthesis. In contrast, 6-thioguanine was more inhibitory to RNA synthesis, and treatment with this drug caused a fall in TfR expression. Thus, although CCRF-CEM cells treated with DFOA show enhanced TfR expression, similar effects are also seen with other inhibitors of DNA synthesis, provided that RNA synthesis is allowed to continue. These results provide further evidence that the regulation of TfR expression by proliferating cells is specifically linked to DNA synthesis rather than to the iron requirements of other cellular processes.     

Altered expression of iron transport proteins in streptozotocin-induced diabetic rat kidney

Diabetes mellitus is associated with altered iron homeostasis in both human and animal diabetic models. Iron is a metal oxidant capable of generating reactive oxygen species (ROS) and has been postulated to contribute to diabetic nephropathy. Two proteins involved in iron metabolism that are expressed in the kidney are the divalent metal transporter, DMT1 (Slc11a2), and the Transferrin Receptor (TfR). Thus, we investigated whether renal DMT1 or TfR expression is altered in diabetes, as this could potentially affect ROS generation and contribute to diabetic nephropathy. Rats were rendered diabetic with streptozotocin (STZ-diabetes) and renal DMT1 and TfR expression studied using semi-quantitative immunoblotting and immunofluorescence. In STZ-diabetic Sprague-Dawley rats, renal DMT1 expression was significantly reduced and TfR expression increased after 2 weeks. DMT1 downregulation was observed in both proximal tubules and collecting ducts. Renal DMT1 expression was also decreased in Wistar rats following 12 weeks of STZ-diabetes, an effect that was fully corrected by insulin-replacement but not by cotreatment with the aldose reductase inhibitor, sorbinil. Increased renal TfR expression was also observed in STZ-diabetic Wistar rats together with elevated cellular iron accumulation. Together these data demonstrate renal DMT1 downregulation and TfR upregulation in STZ-diabetes. Whilst the consequence of altered DMT1 expression on renal iron handling and oxidant damage remains to be determined, the attenuation of the putative lysosomal iron exit pathway in proximal tubules could potentially explain lysosomal iron accumulation reported in human diabetes and STZ-diabetic animals.     

Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis

Although the recent identification of several genes has extended our knowledge on the maintenance of body iron homeostasis, their tissue specific expression patterns and the underlying regulatory networks are poorly understood. We studied C57black/Sv129 mice and HFE knockout (HFE -/-) variants thereof as a model for hemochromatosis, and investigated the expression of iron metabolism genes in the duodenum, liver, and kidney as a function of dietary iron challenge. In HFE +/+ mice dietary iron supplementation increased hepatic expression of hepcidin which was paralleled by decreased iron regulatory protein (IRP) activity, and reduced expression of divalent metal transporter-1 (DMT-1) and duodenal cytochrome b (Dcytb) in the enterocyte. In HFE -/- mice hepcidin formation was diminished upon iron challenge which was associated with decreased hepatic transferrin receptor (TfR)-2 levels. Accordingly, HFE -/- mice presented with high duodenal Dcytb and DMT-1 levels, and increased IRP and TfR expression, suggesting iron deficiency in the enterocyte and increased iron absorption. In parallel, HFE -/- resulted in reduced renal expression of Dcytb and DMT-1. Our data suggest that the feed back regulation of duodenal iron absorption by hepcidin is impaired in HFE -/- mice, a model for genetic hemochromatosis. This change may be linked to inappropriate iron sensing by the liver based on decreased TfR-2 expression, resulting in reduced circulating hepcidin levels and an inappropriate up-regulation of Dcytb and DMT-1 driven iron absorption. In addition, iron excretion/reabsorption by the kidneys may be altered, which may aggravate progressive iron overload.     

Increased expression of transferrin receptor on membrane of erythroblasts in strenuously exercised rats.

This study investigated the effects of strenuous exercise on transferrin (Tf)-receptor (TfR) expression and Tf-bound iron (Tf-Fe) uptake in erythroblasts of rat bone marrow. Female Sprague-Dawley rats were randomly assigned to either an exercise or sedentary group. Animals in the exercise group swam 2 h/day for 3 mo in a glass swimming basin. Both groups received the same amount of handling. At the end of 3 mo, the bone marrow erythroblasts were freshly isolated for Tf-binding assay and determination of Tf-Fe uptake in vitro. Tissue nonheme iron and hematological iron indexes were measured. The number of Tf-binding sites found in erythroblasts was approximately 674,500 +/- 132,766 and 1,270,011 +/- 235,321 molecules/cell in control and exercised rats, respectively (P < 0. 05). Total Fe and Tf uptake by the cells was also significantly increased in the exercised rats after 30 min of incubation. Rates of cellular Fe accumulation were 5.68 and 2.58 fmol. 10(6) cells(-1). min(-1) in the exercised and control rats, respectively (P < 0.05). Tf recycling time and TfR affinity were not different in exercised and control rats. Increased cellular Fe was mainly located in the stromal fraction, suggesting that most of accumulated Fe was transported to the mitochondria for heme synthesis. The findings demonstrated that the increased cellular Fe uptake in exercised rats was a consequence of the increased TfR expression rather than the changes in TfR affinity and Tf recycling time. The increase in TfR expression and cellular Fe accumulation, as well as the decreased serum Fe concentration and nonheme Fe in the liver and the spleen induced by exercise, probably represented the early signs of Fe deficiency.     

Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasis

HFE, the protein that is mutated in hereditary haemochromatosis, binds to the transferrin receptor (TfR). Here we show that wild-type HFE and TfR localize in endosomes and at the basolateral membrane of a polarized duodenal epithelial cell line, whereas the primary haemochromatosis HFE mutant, and another mutant with impaired TfR-binding ability accumulate in the ER/Golgi and at the basolateral membrane, respectively. Levels of the iron-storage protein ferritin are greatly reduced and those of TfR are slightly increased in cells expressing wild-type HFE, but not in cells expressing either mutant. Addition of an endosomal-targeting sequence derived from the human low-density lipoprotein receptor (LDLR) to the TfR-binding-impaired mutant restores its endosomal localization but not ferritin reduction or TfR elevation. Thus, binding to TfR is required for transport of HFE to endosomes and regulation of intracellular iron homeostasis, but not for basolateral surface expression of HFE.     

Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo

In most cells, transferrin receptor (TfR1)-mediated endocytosis is a major pathway for cellular iron uptake. We recently cloned the human transferrin receptor 2 (TfR2) gene, which encodes a second receptor for transferrin (Kawabata, H., Yang, R., Hirama, T., Vuong, P. T., Kawano, S., Gombart, A. F., and Koeffler, H. P. (1999) J. Biol. Chem. 274, 20826-20832). In the present study, the regulation of TfR2 expression and function was investigated. A select Chinese hamster ovary (CHO)-TRVb cell line that does not express either TfR1 or TfR2 was stably transfected with either TfR1 or TfR2-alpha cDNA. TfR2-alpha-expressing cells had considerably lower affinity for holotransferrin when compared with TfR1-expressing CHO cells. Interestingly, in contrast to TfR1, expression of TfR2 mRNA in K562 cells was not up-regulated by desferrioxamine (DFO), a cell membrane-permeable iron chelator. In MG63 cells, expression of TfR2 mRNA was regulated in the cell cycle with the highest expression in late G(1) phase and no expression in G(0)/G(1). DFO reduced cell proliferation and DNA synthesis of CHO-TRVb control cells, whereas it had little effect on TfR2-alpha-expressing CHO cells when measured by clonogenic and cell cycle analysis. In addition, CHO cells that express TfR2-alpha developed into tumors in nude mice whereas CHO control cells did not. In conclusion, TfR2 expression may be regulated by the cell cycle rather than cellular iron status and may support cell growth both in vitro and in vivo.